Fortier, Louis-Charles

Professeur, Faculté de médecine et des sciences de la santé
FMSS Dép. de microbiologie et infectiologie

Coordonnées

Courriel


819-821-8000, poste 75322


Site Web

Diplômes

(2007) Postdoctorat (Postdoctorat en sciences). Université Laval.

(2001) Doctorat (Doctorat en science des aliments). McGill University.

(1996) Maîtrise avec mémoire (Maîtrise ès Sciences - Maîtrise). Université de Sherbrooke.

(1994) Baccalauréat (Baccalauréat en Biologie). Université de Sherbrooke.

Présentation

Sujets de recherche

Infections bactériennes, Mécanismes biologiques et biochimiques, Micro-organismes, Virus (Organismes vivants).

Disciplines de recherche

Microbiologie, Virologie.

Mots-clés

Bactériophages, Bioinformatique-génomique-transcriptomique, Biologie moléculaire, Clostridium difficile, Expression de protéines, Expression génique, Microbiologie, Microscopie électronique, PCR en temps réel, Sporulation.

Intérêts de recherche

Clostridium difficileJe m'intéresse aux infections à en général, incluant les aspects épidémiologiques, la pathogenèse des infections, la virulence et l'évolution de et le développement de nouveaux traitements contre les infections à . J'ai un intérêt particulier pour les bactériophages infectant et le rôle que ceux-ci jouent dans l'évolution de la bactérie et dans l'intestin.

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Prix et distinctions

  • (2017) Pharmacology prize / Prix de Pharmacologie. Université de Sherbrooke. (Prix / Récompense).
  • (2016) Junior 2 Salary Award. Fonds de recherche du Québec - Santé (FRQS). (Prix / Récompense).
  • (2012) Junior 1 Salary Award. Fonds de recherche du Québec - Santé (FRQS). (Prix / Récompense).
  • (2008) Salary award. I got this award from the CRCHUS based on my good ranking at the previous FRQS Junior 1 competition (I got my Junior 1 award on the second try). Centre de recherche clinique Étienne-Le Bel. (Prix / Récompense).
  • (2007) Postdoc scholarship. CRMUS. (Prix / Récompense).
  • (2000) PhD Scholarship. Fondation des Gouverneurs - Agriculture Canada (CRDA, St-Hyacinthe). (Prix / Récompense).
  • (1999) PhD scholarship. FCAR. (Prix / Récompense).
  • (1998) First prize-oral competition-biotechnology. Institute of Food Technology. (Prix / Récompense).
  • (1997) PhD Scholarship from the French Government. French Government. (Prix / Récompense).
  • (1996) M.Sc. Scholarship. Medical Research Council of Canada. (Prix / Récompense).
  • (1995) M.Sc. Scholarship. Faculty of medicine of the Université de Sherbrooke. (Prix / Récompense).

Financement

Subvention. (En cours d’évaluation). Chercheur principal. CRISPR-based engineering of Clostridium difficile bacteriophages for medical applications. (2018-2023).

Subvention. (En cours d’évaluation). Co-chercheur. Epithelial cell-specific role of SOCS1 in protection against inflammatory bowel diseases. (2018-2023).

Subvention. (En cours d’évaluation). Co-chercheur. Microbiota and preterm birth / Microbiote et prématurité. (2017-2020).

Subvention. (En cours d’évaluation). Co-chercheur. Intestinal microbiota and preterm birth/Microbiote intestinal et prématurité. (2017-2019).

Subvention. (Obtenu). Co-chercheur. Développement d'un modèle animal de déclenchement du travail par modification du microbiote intestinal pour une meilleure compréhension des facteurs impliqués dans la prématurité. (2017-2019).

Subvention. (Obtenu). Co-chercheur. Microbiote intestinal en grossesse et prématurité. (2017-2019).

Subvention. (Obtenu). Co-chercheur. Prophylactic and therapeutic use of chenodeoxycholic acid (CDCA) against Clostridium difficile infection. (2016-2018).

Contrat. (Terminé). Chercheur principal. Therapeutic and prophylactic potential of egg yolk antibodies in the fight against Clostridium difficile infections. (2015-2016).

Subvention. (En cours d’évaluation). Co-chercheur. Anti-germination inhibitors as a novel therapeutic venue to treat C. difficile infections.

Publications

Articles de revue

  • Yan LH, Le Roux A, Boyapelly K, Lamontagne AM, Archambault MA, Picard-Jean F, Lalonde-Seguin D, St-Pierre E, Najmanovich RJ, Fortier LC, Lafontaine D, Marsault É. (2018). Clostridioides difficilePurine analogs targeting the guanine riboswitch as potential antibiotics against . European Journal of Medicinal Chemistry, 143, 755-757. (Article publié).
  • Garneau J, Sekulovic O, Dupuy B, Soutourina O, Monot M, Fortier LC. (2018). High Prevalence and Genetic Diversity of Large phiCD211 (phiCDIF1296T)-Like Prophages in Clostridioides difficile. Applied and Environmental Microbiology, 84(3), e02164-17. (Article publié).
  • Allard M*, Bergeron J*, Baharnoori M, Srivastava L, Fortier LC, Poyart C, Sébire G. (2017). A sexually dichotomous, autistic-like phenotype is induced by Group B Streptococcus maternofetal immune activation. Autism Research, 10(2), 233-245. (Article publié).
  • Tremblay S, *Côté NML, Grenier G, Duclos-Lasnier G, Fortier LC, Ilangumaran S, Menendez A. (2017). Ileal antimicrobial peptide expression isdysregulated in old age. Immunity & Aging, 14(19), 1-5. (Article publié).
  • *Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data. Scientific Reports, 7, 1-10. (Article publié).
  • Bergeron J, Gerges N, Guiraut C, Djordje Grbic, Allard MJ, Fortier LC, Vaillancourt C, Sébire G. (2016). Activation of the IL-1β/CXCL1/MMP-10 axis in chorioamnionitis induced by inactivated Group B Streptococcus. Placenta, 47, 116-123. (Article publié).
  • Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold WL, Muller MP, Powis J, Katz K, *Garneau JR, Fortier LC, Pépin J, Cadarette SM, Valiquette L. (2015). Clostridium difficileFactors Associated With Complications of Infection in a Multicenter Prospective Cohort. Clinical Infectious Diseases, 61(12), 1781-1788. (Article publié).
  • Boudry P, Semenova E, Monot M, Datsenko KA, Lopatina A, *Sekulovic O, *Ospina-Bedoya M, Fortier LC, Severinov K, Dupuy B, Soutourina O. (2015). Clostridium difficileFunction of the CRISPR-Cas System of the Human Pathogen . mBio, 6(5), e01112-15. (Article publié).
  • *Sekulovic O, *Ospina Bedoya M, Fivian-Hughes AS, Fariweather NF, Fortier LC. (2015). Clostridium difficileThe Cell Wall Protein CwpV Confers Phase-Variable Phage Resistance. Molecular Microbiology, 98(2), 329-342. (Article publié).
  • Bordeleau E, Purcell EB, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2015). Cyclic-di-GMP riboswitch-regulated type IV pili contribute to aggregation of Clostridium difficile. Journal of Bacteriology, 197(5), 819-832. (Article publié).
  • Bergeron J, Deslauriers J, Grignon S, Fortier LC, Lepage M, Stroh T, Poyart C, Sébire G. (2015). Exposition to group B streptococcal maternalinflammation: White matter injury and autistic-like behavior predominantlyaffecting male rat offspring. Int J Dev Neurosci, 47(A), 47-48. (Article publié).
  • *Sekulovic O, Fortier LC. (2015). Global transcriptional response of Clostridium difficile carrying the ϕCD38-2 prophage. Applied and Environmental Microbiology, 81(4), 1364-1374. (Article publié).
  • Allard MJ, Bergeron J, Grbic D, Fortier LC, Poyart C, Sébire G. (2015). StreptococcusGroup B infection during gestation induces gender specific neurodevelopmentalimpairments. Int J Dev Neurosci, 61(12), 86. (Article publié).
  • *Sekulovic O, *Garneau JR, *Néron A, Fortier LC. (2014). Characterization of Temperate Phages Infecting Clostridium difficile Isolates from Human and Animal Origin. Applied and environmental microbiology, 80(8), 2555-2563. (Article publié).
  • *Garneau JR, Valiquette L, Fortier LC. (2014). Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC infectious diseases, 14(1), 29. (Article publié).
  • Fortier LC, *Sekulovic O. (2013). Importance of prophages to evolution and virulence of bacterial pathogens. Virulence, 4(5), 354-365. (Article publié).
  • Bergeron JD , Deslauriers J , Grignon S , Fortier LC , Lepage M , Stroh T , Poyart C , Sébire G. (2013). White matter injury and autistic-like behavior predominantly affecting male rat offspring exposed to group B streptococcal maternal inflammation. Developmental neuroscience, 35(6), 504-515. (Article publié).
  • *Meessen-Pinard M , *Sekulovic O , Fortier LC. (2012). Evidence of in vivo prophage induction during Clostridium difficile infection. Applied and environmental microbiology, 78(21), 7662-7670. (Article publié).
  • Gebhart D , Williams SR , Bishop-Lilly KA , Govoni GR , Willner KM , Butani A , Sozhamannan S , Martin D , Fortier LC , Scholl D. (2012). Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile. Journal of bacteriology, 194(22), 6240-6247. (Article publié).
  • *Sirard S , Valiquette L , Fortier LC. (2011). Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. Journal of clinical microbiology, 49(12), 4040-4046. (Article publié).
  • *Sekulovic O , *Meessen-Pinard M , Fortier LC. (2011). Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. Journal of bacteriology, 193(11), 2726-2734. (Article publié).
  • Bordeleau E , Fortier LC , Malouin F , Burrus V. (2011). c-di-GMP turn-over in Clostridium difficile is controlled by a plethora of diguanylate cyclases and phosphodiesterases. PLoS genetics, 7(3), e1002039. (Article publié).
  • Gonzales M , Pepin J , Frost EH , Carrier JC , Sirard S , Fortier LC , Valiquette L. (2010). Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC infectious diseases, 10, (Article publié).
  • Mulhbacher J , Brouillette E , Allard M , Fortier LC , Malouin F , Lafontaine DA. (2010). Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS pathogens, 6(4), e1000865. (Article publié).
  • Matte I , Lane D , Côté E , Asselin AE , Fortier LC , Asselin C , Piché A. (2009). Antiapoptotic proteins Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells. Infection and immunity, 77(12), (Article publié).
  • Haaber J , Moineau S , Fortier LC , Hammer K. (2008). AbiV, a novel antiphage abortive infection mechanism on the chromosome of Lactococcus lactis subsp. cremoris MG1363. Applied and environmental microbiology, 74(21), (Article publié).
  • Fortier LC , Moineau S. (2007). Morphological and genetic diversity of temperate phages in Clostridium difficile. Applied and environmental microbiology, 73(22), (Article publié).
  • Fortier LC , Bransi A , Moineau S. (2006). Genome sequence and global gene expression of Q54, a new phage species linking the 936 and c2 phage species of Lactococcus lactis. Journal of bacteriology, 188(17), (Article publié).
  • Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. (2006). The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug metabolism and disposition: the biological fate of chemicals, 34(7), (Article publié).
  • Fortier LC , Bouchard JD , Moineau S. (2005). Expression and site-directed mutagenesis of the lactococcal abortive phage infection protein AbiK. Journal of bacteriology, 187(11), (Article publié).
  • Girard H , Thibaudeau J , Court MH , Fortier LC , Villeneuve L , Caron P , Hao Q , von Moltke LL , Greenblatt DJ , Guillemette C. (2005). UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology (Baltimore, Md.), 42(2), (Article publié).
  • Girard H , Court MH , Bernard O , Fortier LC , Villeneuve L , Hao Q , Greenblatt DJ , von Moltke LL , Perussed L , Guillemette C. (2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics, 14(8), (Article publié).
  • Fortier LC , Tourdot-Maréchal R , Diviès C , Lee BH , Guzzo J. (2003). Induction of Oenococcus oeni H+-ATPase activity and mRNA transcription under acidic conditions. FEMS microbiology letters, 222(2), (Article publié).
  • Villeneuve L , Girard H , Fortier LC , Gagné JF , Guillemette C. (2003). Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. The Journal of pharmacology and experimental therapeutics, 307(1), (Article publié).
  • Guzzo J , Jobin MP , Delmas F , Fortier LC , Garmyn D , Tourdot-Maréchal R , Lee B , Diviès C. (2000). Regulation of stress response in Oenococcus oeni as a function of environmental changes and growth phase. International journal of food microbiology, 55(1-3), (Article publié).
  • Tourdot-Maréchal R , Fortier LC , Guzzo J , Lee B , Diviès C. (1999). Acid sensitivity of neomycin-resistant mutants of Oenococcus oeni: a relationship between reduction of ATPase activity and lack of malolactic activity. FEMS microbiology letters, 178(2), (Article publié).
  • Fortier LC , Delbecchi L , Bourgaux-Ramoisy D , Bourgaux P. (1998). Rescue of polyomavirus DNA after co-transfection of recombinant plasmids with viral DNA fragments. Biochimica et biophysica acta, 1395(1), (Article publié).

Chapitres de livre

  • Fortier, LC. (2017). The contribution of bacteriophages to the biology and virulence of pathogenic clostridia. Advances in Applied Microbiology (101, 1-10). Elsevier. (Article sous presse).
  • Sekulovic O, Fortier LC. (2016). Characterization of functional prophages in Clostridium difficile. Methods in Molecular Biology - Clostridium difficile. Invited chapter (476, 143-65). Humana Press. (Article publié).
  • Fortier LC, Moineau S. (2009). Phage production and maintenance of stocks, including expected stock lifetimes. Methods in Molecular biology (501, 203-219). Clokie MRJ and AM Kropinski. (Article publié).

Articles de conférence

  • Pasquier JC, Lewin A, St-Pierre E, Gillet V, Fortier LC. (2017). Fecal transplants disturb length of pregnancy in a mouse model. 37th Annual pregnancy meeting of the Society of Maternal-Fetal Medicine (SMFM) (Jan 23-28). Las Vegas, NV, USA. (Article publié).
  • Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). PhageTerm: a Fast and User-friendly Software to Determine Bacteriophage Termini and Packaging Mode using randomly fragmented NGS data. Centennial Celebration of Bacteriophage Research (April 24-26). Institut Pasteur, Paris, France. (Article accepté).
  • Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). Phageterm: a fast and user-friendly software todetermine bacteriophage termini and packaging mode using randomly fragmented NGSdata. Annual meeting of the Canadian Society for Microbiologists (CSM) (June 20-23) Waterloo, ON, Canada. (Article accepté).
  • Allard MJ, Guiraut C, Descoteaux M, Tremblay L, Lepage M, Fortier LC, Sébire G. (2017). StreptococcusPlacental group B infection: sex specific inflammatory response andautistic-like traits in male offspring. Meeting of the International Society for Autism Research (INSAR/IMFAR) (May 10-13). San Francisco, CA, USA. (Article accepté).
  • Larocque M, Fortier LC, Najmanovich R. (2016). Clostridium difficileIntegrative approach in drugs discovery pipeline applied to . ISMB/SigBio joint meetings, Orlando, FL, USA July 8-12. (Article publié).
  • Garneau JR, Monot M, Valiquette L, Fortier LC. (2016). Clostridium difficileProphage elements as a significant source of genetic diversity among epidemic R027 clinical isolates of . Annual meeting of the Canadian Society for Microbiologists (CSM). (Article publié).
  • Ospina-Bedoya M, Fagan R, Govoni G, Fortier LC. (2016). Clostridium difficileRole of the Surface Layer Protein A in bacteriophage infection. Annual meeting of the Canadian Society for Microbiologists (CSM). (Article publié).
  • Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold W, Muller MP, Devlin R, Powis J, Katz K, Garneau JR, Fortier LC, Pépin J, Valiquette L. (2015). Clostridium difficileIndependent Risk Factors for Recurrence of Infection: ACanadian Multicenter Prospective Cohort. IDWeek. (Article publié).
  • Garneau JR, Abou Chakra CN, Labbé AC, McGeer A, Pépin J, Valiquette L, Fortier LC. (2015). ClostridiumdifficileRelationship between MLVA genetic types andclinical outcomes following infection by ribotype 027. 5th ICDS meeting. (Article publié).
  • Michaud A, Smith-Peter E, Lafontaine DA, Fortier LC. (2015). Clostridium difficileThe riboswitch-controlled GMP synthase GuaA is important for survival andvirulence of and in a mouse model ofinfection. Annual meeting of the RiboClub. (Article publié).
  • Sekulovic O, Fortier LC. (2014). Clostridium difficileA first glance atphage-host interactions in . General meeting of the American Society for Microbiology (ASM. (Article publié).
  • Garneau JR, Abou Chakra CN, Fortier LC, Labbé AC, McGeer A, Pépin J, Valiquette L. (2014). Clostridium difficileAnalyse de l'impact des types génétiques bactériens MLVA sur les issues cliniques d'infection par ribotype 027. Annual meeting of the Association des Médecins Microbiologistes infectiologues du Québec - AMMIQ. (Article publié).
  • Bordeleau E, Purcell EB, Paquette-D’Avignon M, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2014). Cyclic-di-GMP signaling and type IV pili-mediated aggregation in Clostridium difficile. 114th General meeting of the America Society for Microbiology (ASM). (Article publié).
  • Allard MJ, Bergeron J, Grbic D, Fortier LC, Poyart C, Sébire G. (2014). StreptococcusGroup B infection during gestation induces gender specific neurodevelopmentalimpairments. Joint Meeting of the 20th Biennial Meeting of the International Society for Developmental Neuroscience and the 5th Annual NeuroDevNet Brain Development Conference (ISDN, NeuroDevNet 2014). (Article publié).
  • Allard MJ, Bergeron J, Fortier LC, Poyart C, Sébire G. (2014). StreptococcusGroup B infection during gestation leads to gender specific neurodevelopmental andbehavioural impairments. Annual Meeting of the Society for Neuroscience. (Article publié).
  • Garneau JR, Sekulovic O, Néron A, Fortier LC. (2014). Temperate phages of Clostridium difficile isolated from farm animals. 114th General meeting of the America Society for Microbiology (ASM). (Article publié).
  • Sekulovic O, Fortier LC. (2013). A First Glance at Phage-Host Interactions in Clostridium difficile. 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. (Article publié).
  • Bergeron J, Brochu ME, Deslauriers J, Grignon S, Fortier LC, Sébire G. (2013). Gestational exposure to inactivated Group B Streptococcus induced gender-dependent brain damage and autistic features in offspring. Pediatric Academic Societies/Eastern Society for Pediatric Research Annual Meeting. (Article publié).
  • Bergeron J, Allard MJ, Deslauriers J, Grignon S, Sarret P, Fortier LC, Poyart C, Sébire G. (2013). Group B Streptococcus inflammatory response induced during gestation recapitulates perinatal injuries and subsequent behavioral impairments affecting premature human newborn such as autistic features in male offspring. Meeting of the Society for Neuroscience. (Article publié).
  • Abou Chakra CN, Labbé AC, McGeer A, Simor A, Gold W, Devlin R, Katz K, Powis J, Fortier LC, Muller MP, Garneau JR, Pepin J, Valiquette L. (2013). Risk factors for complications of Clostridium difficile Infection in a prospective multicentre cohort. IDWeek. (Article publié).
  • Gebhart D, Scholl D, Vacin C, Fortier LC, Williams S, Govoni G. (2012). Diffocins: novel, high-molecular weight bacteriocins highly specific for Clostridium difficile. 4th International Conference on Clostridium difficile (4th ICDS). (Article publié).
  • St-Pierre E, Lalonde Séguin D, Burrus V, Fortier LC. (2012). Inactivation of chemotaxis-associated genes increases flagellar motility in Clostridium difficile. 4th International Conference on Clostridium difficile (4th ICDS). (Article publié).
  • Garneau JR, Valiquette L, Fortier LC. (2012). La sporulation de Clostridium difficile est inhibée par des concentrations sous-inhibitrices de tigecycline et de piperacillin-tazobactam in vitro. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • St-Pierre E, Pépin ME, Burrus V, Fortier LC. (2012). Rôle de la mobilité et du chimiotactisme dans la virulence de Clostridium difficile. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Kelly M, Fortier LC. (2011). Antimicrobial activity of beta-bio 45% hops extract against Clostridium difficile NAP1/027 (Abstract #32532). 49th Annual Meeting of the Infectious Diseases Society of America - IDSA. (Article publié).
  • Sirard S, Valiquette L, Fortier LC. (2011). Can the clinical outcomes associated with Clostridium difficile Infections (CDI) be predicted by bacterial genotype and phenotypes?. Annual meeting of the Association des Médecins Microbiologistes infectiologues - AMMI. (Article publié).
  • Bergeron J, Girard S, Brochu ME, Fortier LC, Sébire G. (2011). Implication du Streptocoque de groupe B dans les lésions cérébrales périnatales. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Gebhart D, Williams S, Fortier LC, Govoni G, Scholl D. (2011). Phage tail-like bacteriocins of Clostridium difficile. 7th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (ClosPath). (Article publié).
  • Bergeron J, Girard S, Brochu ME, Fortier LC, Sebire G. (2011). Role of gestational inflammation induced by group B streptococcus in perinatal brain lesions and subsequent cerebral palsy. 40th Annual Meeting of the Child Neurology Society. (Article publié).
  • Néron A, Sekulovic O, Fortier LC. (2010). Diversité et biologie des bacteriophages de Clostridium difficile isolés de souches animales. Annual Pharmacology meeting, faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Pinard MM, Fortier LC. (2010). In vivo prophage induction in patients infected by Clostridium difficile. Viruses of Microbes meeting. (Article publié).
  • Bergeron J, Girard S, Brochu ME, Fortier LC, Sébire G. (2010). Mise au point d’un modèle animal de paralysie cérébrale par exposition gestationnelle au Streptocoque de groupe B inactivé. Annual meeting of Pediatrics, Sherbrooke hospital center (CHUS). (Article publié).
  • Sirard S, Valiquette L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur le phénotype et le génotype bactériens ?. 39th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Sirard, S, Valiquette, L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur l’analyse génotypique et phénotypique des souches bactériennes?. 78th Meeting of the ACFAS. (Article publié).
  • Sekulovic O, Fortier LC. (2010). Prophage-enhanced toxin production in Clostridium difficile NAP1/027 lysogens. Viruses of Microbes meeting. (Article publié).
  • Sirard S, Valiquette L, Fortier LC. (2010). Prédire la sévérité des infections à C. difficile : plus difficile qu’il n’y paraît !. Annual research meeting of the Université de Sherbrooke. (Article publié).
  • Fortier LC, Matte I, Côté É, Asselin A-É, Asselin C, Piché A. (2009). Anti-apoptotic proteins Bcl-2/Bcl-XL protect from Clostridium difficile toxin A-induced cell death. 26th International Congress of Chemotherapy and Infection (ICC). (Article publié).
  • Sekulovic O, Fortier LC. (2009). Impact des prophages sur la biologie de Clostridium difficile. 38th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Pinard MM, Fortier LC. (2009). La phagothérapie contre Clostridium difficile : une réalité ?. 38th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Mauler S, Pinard MM, Sekulovic O, Fortier LC. (2009). Les bactériophages contre C. difficile : réalité ou utopie ?. Annual research meeting of the Université de Sherbrooke. (Article publié).
  • Haaber J, Moineau S, Fortier LC, Hammer K. (2008). AbiV, a novel abortive phage infection mechanism on the chromosome of Lactococcus lactis subsp. cremoris MG1363. 9th Symposium on Lactic Acid Bacteria. (Article publié).
  • Pinard MM, Sekulovic O, Fortier LC. (2008). Les phages de Clostridium difficile : rôle dans la virulence et potentiel thérapeutique. 37th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Pinard MM, Sekulovic O, Fortier LC. (2008). Les phages de Clostridium difficile : rôle dans la virulence et potentiel thérapeutique. Annual research meeting of the Université de Sherbrooke. (Article publié).
  • Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. 37th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. Annual research meeting of the Université de Sherbrooke. (Article publié).

Propriétés intellectuelles

Brevets

  • (2016). C. difficile antibodies directed thereto, and target for the treatment of humans and other animals intoxicated with at least one bacterial toxin A and/or B. 62118450. Canada. (Délivré).

Autres contributions

Cours enseignés

  • Antimicrobiens et chimiothérapie. PHR305. (2017-09-01). Université de Sherbrooke. Canada.
  • Microbiologie en pharmacologie. MCB103. (2016-09-01). Université de Sherbrooke. Canada.
  • Le microbiome dans la physiologie, l'immunologie et le métabolisme de l'hôte. MCR717. (2016-01-01). Université de Sherbrooke. Canada.

Activités de collaboration internationale

  • Principal investigator and Collaborator. (2012-2020). France. My team started to collaborate with a group at the Institut Pasteur in Paris, i.e. Olga Soutourina, Marc Monot and Bruno Dupuy. The research project is on CRISPRs in Clostridium difficile. Our implication is on the characterization of phages and the correlation between phage susceptibility and the presence of specific CRISPR cassettes in C. difficile. My group provides all the phage expertise and phage material. The group in France also contributed in phage genome sequencing project. Two of my students have been involved in the project so far: Ognjen Sekulovic (PhD candidate) and Maicol Ospina Bedoya (MSc candidate). A collaborative paper has been submitted to mBio in July 2015 (under review).
  • Principal investigator. (2017-2019). États-Unis.
  • Collaborator. (2012-2018). États-Unis. I have participated in a research collaboration with the private company AvidBiotics in South San Francisco (CA, USA). They have started studying phage tail-like particles that I had identified and described earlier in a paper (Fortier and Moineau, AEM 2007). I shared with them bacterial strains, protocols and my expertise. I also performed electron microscopy analyses and contributed to the preparation of the manuscript that we published together in 2012 (Gebhart et al, JBacteriol 2012). Now we are collaborating on the characterization of phage receptors.
  • Principal investigator. (2013-2015). Royaume-Uni. We started to collaborate with the group of Neil Fairweather on the study of the cell wall associated protein CwpV in C. difficile. They shared with us various constructions of CwpV and antibodies and we shared our recent research results with them. They are co-authors of a publication with us (Sekulovic et al, Mol. Microbiol. 2015, in press). Our objective is to work together to try to clarify the biological function of CwpV.

Présentations

  • (2017). Interactions phages-hôte chez Clostridium difficile. Université Laval - Conférence invitée. Québec, Canada.
  • (2016). Interactions phages-hôte chez la bactérie pathogène Clostridium difficile. Conferences of the department of Immunology of the faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.
  • (2016). La prescription des phages. French conference in medicine of Moncton. Moncton, Canada.
  • (2015). Le développement d'un nouvel antibiotique: de l'idée à la clinique. CursUS-Santé. Sherbrooke, Canada.
  • (2015). Phage-host interactions in Clostridium difficile. Invited speaker at the Institut Pasteur in Paris, France. Paris, France.
  • (2015). The phase-variable cell wall protein CwpV confers phage resistance to Clostridium difficile. *This abstract was selected for an oral presentation by the review committee. 5th ICDS meeting. Bled, Slovénie.
  • (2014). "Les superbactéries, doit-on s'en préoccuper?" Superbugs, should we be preoccupied? I was invited as a microbiology expert (along with 3 other microbiologists) to discuss this topic with the public. Les grands rendez-vous scientifiques du Musée de l'Institut Armand-Frapier. Laval, Canada.
  • (2014). A first glance at phage-host interactions in Clostridium difficile. * This abstract was selected for an oral presentation by the review committee, and won the Gisela Mosig prize for best abstract. General meeting of the American Society for Microbiology (ASM). Boston, États-Unis.
  • (2014). Développement d'une plateforme pour l'étude du microbiote intestinal. Technological conferences of the research axis in inflammation and pain of the CHUS research center. Sherbrooke, Canada.
  • (2014). Impact des antibiotiques sur la susceptibilité aux infections à Clostridium difficile: une approche intégrative. 56e réunion annuelle du Club de Recherche Clinique du Québec. Mont Gabriel, Canada.
  • (2014). The guanine riboswitch as a target for the treatment of C. difficile and S. aureus infections. Second presentation in front of potential investors (Amorchem, Neomed and MSBiV). Montréal, Canada.
  • (2013). Cyclic-di-GMP riboswitch-controlled type IV pili-mediated aggregation in Clostridium difficile. 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. Palm Cove, Australie.
  • (2013). Impact des antibiotiques sur la susceptibilité aux infections à Clostridium difficile: une approche integrative. First annual meeting of the Research Center on Inflammation and Cancer of the Université de Sherbrooke (CRICUS). Sherbrooke, Canada.
  • (2013). Pathogenèse des infections à Clostridium difficile et développement de nouveaux antibiotiques. Annual research forum of the faculty of medicine of the Université de Sherbrooke. Magog, Canada.
  • (2013). Phage-host interactions in the human pathogen Clostridium difficile. Seminars series at Memorial University. St-John's, Canada.
  • (2013). The guanine riboswitch as a target for the treatment of C. difficile and S. aureus infections. First presentation in front of potential investors (Amorchem, Neomed and MSBiV). Montréal, Canada.
  • (2012). Genetic diversity of Clostridium difficile and novel therapeutic strategies. Invited speaker at ViroPharma Inc. Exton, États-Unis.
  • (2012). Pathogenesis of Clostridium difficile infections and novel therapeutic strategies. Invited speaker at AvidBiotics Inc. South San Francisco, États-Unis.
  • (2012). Pathogénèse des infections à Clostridium difficile. Conférences en microbiologie et en biotechnologie. Sherbrooke, Canada.
  • (2011). Pathogenesis of Clostridium difficile infections and development of novel antimicrobial agents. Invited speaker for the annual CIHR Infection and Immunity consulting committee. Sherbrooke, Canada.
  • (2011). Sub-inhibitory concentrations of tigecycline inhibit sporulation of Clostridium difficile in vitro. 7th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. Aymes, États-Unis.
  • (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur l’analyse génotypique et phénotypique des souches bactériennes?. Annual Meeting of the Association des Médecins Microbiologistes Infectiologues du Québec (AMMIQ-JAFA). Québec, Canada.
  • (2010). The multiple facets of bacteriophages and their role in the diversity and virulence of C. difficile. 3rd International Clostridium difficile symposium. Bled, Slovénie.
  • (2009). Guanine riboswitch as a target for new antibiotics family. Invited seminar at the faculty of medicine of the U. of Montreal. Montreal, Canada.
  • (2009). Impact des prophages sur la biologie de Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.
  • (2009). Infections à C. difficile: quand C. difficile, ce n’est jamais simple!. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.
  • (2009). Novel antibioswitches as selective inhibitors of guanine-related metabolic pathways. 10th annual Eastern Ribo-club Opening Session. Magog, Canada.
  • (2009). Prophage-enhanced toxin production in Clostridium difficile NAP1/027 lysogens. "This abstract was selected for a slide presentation by the review committee". 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, États-Unis.
  • (2009). Riboswitch guanine: nouvelle cible pour les antibioswitches. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.
  • (2009). Rôle des bactériophages dans l’évolution et la virulence de Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel. Sherbrooke, Canada.
  • (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. 10th annual Ontario-Québec Biotechnology meeting. Sherbrooke, Canada.
  • (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. Conferences of the Ribo-club. Magog, Canada.
  • (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. RNA meeting. Berlin, Allemagne.
  • (2008). Potential of phage therapy to fight Clostridium difficile infections. Eliava-2008: Phage biology, ecology and therapy meeting. Tbilisi, Géorgie.
  • (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-Le Bel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.